- Home
- RCS vs ZNTL Comparison
RCS vs ZNTL Comparison
Compare RCS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | ZNTL |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.0M | 289.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RCS | ZNTL |
|---|---|---|
| Price | $5.16 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 118.5K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.09 | $1.21 |
| 52 Week High | $8.00 | $6.95 |
Technical Indicators
Market Signals| Indicator | RCS | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 34.45 | 45.35 |
| Support Level | $5.09 | $3.53 |
| Resistance Level | $5.67 | $5.11 |
| Average True Range (ATR) | 0.09 | 0.44 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 5.00 | 5.30 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.